Acalabrutinib + venetoclax: all-oral, fixed-duration CLL

On February 19, 2026 the FDA approved acalabrutinib plus venetoclax for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is the first all-oral, fixed-duration regimen in the frontline setting — no infusions, and a defined stop date rather than treatment until progression. The approval rests on the phase 3 AMPLIFY trial, and the logic behind it is a clean example of why hitting two non-overlapping nodes of the same survival circuit beats pushing harder on either one alone.

Two drugs, two mechanisms

CLL cells survive by leaning on two distinct molecular crutches, and each drug in the combination kicks out one of them.

• Acalabrutinib is a second-generation covalent BTK inhibitor. It forms a bond to Cys481 in the ATP pocket of Bruton tyrosine kinase, shutting down B-cell receptor signaling. Compared to first-generation ibrutinib it is far more selective, sparing EGFR, TEC, and ITK, which is why it carries less atrial fibrillation and bleeding. BTK blockade does not kill CLL cells outright; it pushes them out of the protective lymph-node niche and blocks the proliferation signal.
• Venetoclax is a BH3-mimetic that binds the BCL-2 anti-apoptotic protein, displacing the pro-apoptotic effectors (BIM, BAX, BAK) that BCL-2 normally sequesters. CLL cells are addicted to BCL-2 overexpression to avoid apoptosis, so freeing those effectors triggers programmed cell death directly. Venetoclax is the component that drives deep, measurable-residual-disease-negative responses.

The pairing is rational: acalabrutinib mobilizes the disease and suppresses proliferation while venetoclax delivers the apoptotic kill. Because BTK inhibition reduces tumor bulk first, it also blunts the tumor-lysis-syndrome risk that comes with venetoclax ramp-up.

What AMPLIFY actually showed

AMPLIFY (NCT03836261) randomized fit, treatment-naive CLL patients without del(17p) or TP53 mutation to fixed-duration acalabrutinib plus venetoclax (AV), AV plus obinutuzumab (AVO), or investigator’s choice of chemoimmunotherapy (FCR or BR). The key readout:

• Progression-free survival. Both AV and AVO significantly prolonged PFS versus chemoimmunotherapy. Median PFS on standard chemoimmunotherapy was 47.6 months; on the acalabrutinib-venetoclax arms it was not reached at the interim analysis, with a clinically meaningful absolute gain in 3-year PFS.
• Fixed duration. Unlike continuous BTK-inhibitor monotherapy, the regimen stops after a defined course. Patients get a treatment-free interval, which matters for cost, adherence, and cumulative toxicity.
• Caveat on TP53. The trial excluded del(17p) and TP53-mutated patients, so the label does not extend the strongest evidence to that high-risk group. Adding obinutuzumab (AVO) improved depth of response but added infusion burden and infection risk, which is part of why the all-oral AV doublet is the headline regimen.

Why this matters for structure-based design

Both targets are well-characterized structurally, which makes the combination a useful teaching case for docking. BTK’s Cys481 is the covalent anchor that acalabrutinib exploits — and the same residue, when mutated to serine (C481S), abolishes covalent binding and drives resistance, which is the entire rationale for reversible binders like pirtobrutinib. BCL-2, by contrast, is a protein-protein interaction surface: venetoclax has to occupy a long, shallow groove that small molecules historically struggled to drug, which is why BH3-mimetics took two decades to reach the clinic.

Try the docking yourself

Open Studio and dock acalabrutinib into BTK to see the covalent geometry at Cys481, then switch the receptor to the C481S mutant and watch the covalent anchor disappear. Docking the two drugs against their respective targets side by side is the fastest way to internalize why a covalent BTK binder and a BH3-mimetic are mechanistically independent — and why combining them is more than additive. Molecular docking online makes that comparison a two-minute exercise instead of a modeling project.

Primary sources

• Brown JR, et al. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. N Engl J Med 392, 748-762 (2025). doi:10.1056/NEJMoa2409804
• U.S. Food and Drug Administration. FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma. February 19, 2026. fda.gov
• Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19, 202-208 (2013). doi:10.1038/nm.3048